CanSino Biologics CEO on earnings, business outlook, and international partnerships
Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the impact from US-China trade tensions for the company remains on the margins.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
China Just Froze a $35 Billion U.S. Merger -- And Investors Should Pay Attention
The $35 billion merger between Synopsys (SNPS) and Ansys has hit a significant roadblock as China's antitrust regulator postponed its final approval following renewed U.S. export controls. The proposed tie-up, which had already advanced to the final review stage by China's State Administration for Market Regulation, now faces uncertainty after the Trump administration expanded restrictions on semiconductor design software and other sensitive technologies to China. According to sources cited by the Financial Times, the delay is directly tied to Washington's latest move in late May to restrict sales of chip design toolsaffecting companies like Synopsyswithout special licenses. Warning! GuruFocus has detected 3 Warning Sign with GME. The timing of the setback comes just days after U.S. and Chinese officials reached a tentative truce in London to ease broader trade friction. However, the agreement appears fragile, with Beijing's curbs on critical mineral exports triggering further U.S. clampdowns. As a result, licenses for certain suppliers have been revoked, and a broader licensing regime has been reinstated. For Synopsys and Ansys, these geopolitical shifts now threaten to derail a merger that had already cleared regulatory hurdles in all other jurisdictions except China. Neither company, nor the Chinese regulator, has publicly commented on the reported delay. On the domestic front, the U.S. Federal Trade Commission last month required the divestiture of certain assets to alleviate antitrust concerns tied to the deal. Synopsys CEO has indicated that regulatory approval has been secured globallywith China as the sole outlier. Investors are watching closely as the delay could stretch the closing timeline or possibly trigger renegotiation risks, especially if trade tensions escalate further. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
One Booz Allen Hamilton Holding Insider Raised Their Stake In The Previous Year
Insiders were net buyers of Booz Allen Hamilton Holding Corporation's (NYSE:BAH ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The Independent Director Joan Lordi Amble made the biggest insider purchase in the last 12 months. That single transaction was for US$294k worth of shares at a price of US$147 each. That means that even when the share price was higher than US$103 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Joan Lordi Amble was the only individual insider to buy shares in the last twelve months. Joan Lordi Amble purchased 3.62k shares over the year. The average price per share was US$143. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Booz Allen Hamilton Holding There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Booz Allen Hamilton Holding insiders own 1.6% of the company, worth about US$209m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like Booz Allen Hamilton Holding insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 3 warning signs for Booz Allen Hamilton Holding (1 is a bit unpleasant!) and we strongly recommend you look at these before investing. But note: Booz Allen Hamilton Holding may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
ExlService Holdings (NASDAQ:EXLS) Is Very Good At Capital Allocation
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Speaking of which, we noticed some great changes in ExlService Holdings' (NASDAQ:EXLS) returns on capital, so let's have a look. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for ExlService Holdings, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.20 = US$281m ÷ (US$1.7b - US$244m) (Based on the trailing twelve months to March 2025). Thus, ExlService Holdings has an ROCE of 20%. That's a fantastic return and not only that, it outpaces the average of 14% earned by companies in a similar industry. View our latest analysis for ExlService Holdings Above you can see how the current ROCE for ExlService Holdings compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering ExlService Holdings for free. The trends we've noticed at ExlService Holdings are quite reassuring. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 20%. Basically the business is earning more per dollar of capital invested and in addition to that, 42% more capital is being employed now too. So we're very much inspired by what we're seeing at ExlService Holdings thanks to its ability to profitably reinvest capital. A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what ExlService Holdings has. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. Therefore, we think it would be worth your time to check if these trends are going to continue. ExlService Holdings does have some risks though, and we've spotted 1 warning sign for ExlService Holdings that you might be interested in. If you want to search for more stocks that have been earning high returns, check out this free list of stocks with solid balance sheets that are also earning high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
